Javascript must be enabled to continue!
Early Data Of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated By A Strategy Of Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy
View through CrossRef
Background. Appendiceal peritoneal pseudomyxoma
(PMP) is very rare disease and its longterm
prognosis is poor. The aim of this study was
to evaluate the results of an aggressive treatment
approach used in our institution for the last 4 years.
Methods. We selected all patients with PMP from
appendiceal origin who were treated by cytoreductive
surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) at the Klaipeda University
Hospital between January 2012 and January 2016.
Data from all patients with PMP arising from the
appendix were retrospectively collected and analyzed.
Treatment consisted of complete surgical cytoreduction
, followed by hyperthermic intraperitoneal
chemotherapy with mitomycin at 42°C over
90 minutes. Ronnett’s hystologic classification was
used for tumor grading.
Results. A total of 6 patients underwent cytoreduction
and peritonectomy plus HIPEC. Median
age at diagnosis was 57 years (range, 39-67). All
our patients were female. The previous surgery score
at the moment of admission was PSS-2 for three
patients, PSS-3 for 3 patients. Four patients were
diagnosed as diffuse peritoneal adenomucinosis
(DRAM) and two as peritoneal mucinous carcinomatosis(
PMCA).
In all of the patients, optimal cytoreduction CC-0 (5
patients) and CC-1 (one patient) was achieved. The
median peritoneal cancer index (PCI) was 17 (range,
14-25) as an indicator of disease extension.The
median number of visceral resections performed per patient was 3 (range, 1-5). The median duration of
CRS/HIPEC was 8 hours and 10 minutes (range, 7
hours and10 min. to 9 hours 20 min). Mean postoperative
stay was 13 days (range, 8-18). The 30 days
postoperative and in-hospital mortality were zero .
One patient experienced temporary haemorhagic
cystitis. The mean follow-up period was 28 months
( range, 8-45). At the time of analysis all patients
are alive and without recurrence.
Conclusions PMP from appendiceal origin can be
treated with curative intent in a large percentage of
cases by cytoreductive surgery associated with HIPEC.
This new approach could be performed safely
with acceptable morbidity and mortality in selected
patients treated in specialized centers.
Title: Early Data Of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated By A Strategy Of Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy
Description:
Background.
Appendiceal peritoneal pseudomyxoma
(PMP) is very rare disease and its longterm
prognosis is poor.
The aim of this study was
to evaluate the results of an aggressive treatment
approach used in our institution for the last 4 years.
Methods.
We selected all patients with PMP from
appendiceal origin who were treated by cytoreductive
surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) at the Klaipeda University
Hospital between January 2012 and January 2016.
Data from all patients with PMP arising from the
appendix were retrospectively collected and analyzed.
Treatment consisted of complete surgical cytoreduction
, followed by hyperthermic intraperitoneal
chemotherapy with mitomycin at 42°C over
90 minutes.
Ronnett’s hystologic classification was
used for tumor grading.
Results.
A total of 6 patients underwent cytoreduction
and peritonectomy plus HIPEC.
Median
age at diagnosis was 57 years (range, 39-67).
All
our patients were female.
The previous surgery score
at the moment of admission was PSS-2 for three
patients, PSS-3 for 3 patients.
Four patients were
diagnosed as diffuse peritoneal adenomucinosis
(DRAM) and two as peritoneal mucinous carcinomatosis(
PMCA).
In all of the patients, optimal cytoreduction CC-0 (5
patients) and CC-1 (one patient) was achieved.
The
median peritoneal cancer index (PCI) was 17 (range,
14-25) as an indicator of disease extension.
The
median number of visceral resections performed per patient was 3 (range, 1-5).
The median duration of
CRS/HIPEC was 8 hours and 10 minutes (range, 7
hours and10 min.
to 9 hours 20 min).
Mean postoperative
stay was 13 days (range, 8-18).
The 30 days
postoperative and in-hospital mortality were zero .
One patient experienced temporary haemorhagic
cystitis.
The mean follow-up period was 28 months
( range, 8-45).
At the time of analysis all patients
are alive and without recurrence.
Conclusions PMP from appendiceal origin can be
treated with curative intent in a large percentage of
cases by cytoreductive surgery associated with HIPEC.
This new approach could be performed safely
with acceptable morbidity and mortality in selected
patients treated in specialized centers.
Related Results
Peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy
Peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy
AbstractIntroduction To evaluate the combined treatment with cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from colorectal cancer, ps...
Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin: A Single Center Experience
Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin: A Single Center Experience
Background: Pseudomyxoma peritonei (PMP) originating from appendiceal mucinous neoplasm is a rare peritoneal malignancy characterized by the progressive intraperitoneal accumulatio...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Cytoreduction including total gastrectomy for pseudomyxoma peritonei
Cytoreduction including total gastrectomy for pseudomyxoma peritonei
AbstractBackgroundCytoreductive surgery supplemented by perioperative intraperitoneal chemotherapy is a therapeutic option for selected patients with pseudomyxoma peritonei syndrom...
The surgical management of intrathoracic pseudomyxoma peritonei
The surgical management of intrathoracic pseudomyxoma peritonei
Abstract
Backgrounds: To explore the clinical features, diagnosis, treatment, and prognosis of intrathoracic pseudomyxoma peritonei.
Methods: A retrospective analysis of th...
Pseudomyxoma peritonei: two case study and literatures review
Pseudomyxoma peritonei: two case study and literatures review
Pseudomyxoma peritonei (PMP) is a rare neoplastic illness with unique clinical and pathologic patterns. This disease characterized by being chronic, indolent, and relapsing. It is ...
Appendiceal Neoplasm
Appendiceal Neoplasm
Appendiceal neoplasms are rare and are typically found in the setting of metastatic disease or, less commonly, as an incidental finding in an appendectomy specimen in cases of appe...
Appendiceal Neoplasm
Appendiceal Neoplasm
Appendiceal neoplasms are rare and are typically found in the setting of metastatic disease or, less commonly, as an incidental finding in an appendectomy specimen in cases of appe...

